Lung Cancer Comprehensive Panel

Test Code
SLS160002
Book Now

What is the Lung Cancer Comprehensive Panel?

This comprehensive test evaluates mutations involved in lung cancer in 14 genes using DNA sequencing and fusions in 6 genes using RNA sequencing; it also tests for PDL-1 expression (22C3 antibody), offering a full genetic and immune profile for patients with advanced, complex, or treatment-resistant non-small cell lung cancer.

Genes Covered/ No. of Genes/ Biomarkers Covered: SNVs, InDels, and CNVs in 14 genes (DNA sequencing); Fusions in 6 genes (RNA sequencing); PDL-1 22C3 (Dako)

Who Is This Test For?

Patients with complex or treatment-resistant lung cancer may benefit from broad genomic and immunologic profiling.

Key Features

Covers 14 genes for DNA variants, 6 genes for RNA fusions, and PDL-1 expression for immunotherapy potential

Clinical Applications

  • Supports decisions for targeted treatment, immune checkpoint inhibitors, and combination therapies
  • Detects a wide range of driver mutations and gene fusions across major lung cancer pathways
  • Helps sequence therapies over the course of the disease for optimal management

Lung Cancers

Contact Us